Table 1 ABT-199 enhances chemotherapy-induced cell death in Bcl-2 dependent NBs. SMS-SAN (Bcl-2 dependent) and IMR5 (Mcl-1 dependent) NB cells were exposed to different combinations of ABT-199 + doxorubicin or ABT-199 + melphalan for 48 h then evaluated by WST-1 for changes in IC50 of the combination compared to the cytotoxic chemotherapy given alone. Table numbers represent the average of three biologic experiments
From: Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
Chemotherapy + ABT-199 in vitro combinations | ||
SMS‐SAN (Bcl‐2 Dependent) | IMR-5 Mcl-1 dependent | |
ABT‐199 dosing (nM)a | IC50 Doxorubicin (ng/mL) | IC50 Doxorubicin (ng/mL) |
0 | 493.6 | 412.2 |
1 | 58.49 | 401.9 |
5 | 15.28 | 384.9 |
ABT‐199 dosing (nM)a | IC50 Melphalan (μM) | IC50 Melphalan (μM) |
0 | 6.25 | 15.29 |
1 | 3.3 | 15.39 |
5 | 2.3 | 14.27 |